Insufficient ablation promotes the metastasis of residual non-small cell lung cancer (NSCLC) cells via upregulating carboxypeptidase A4

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503–513.
   PubMed Web of Science ®Google Scholar
• Horeweg N, van Rosmalen J, Heuvelmans MA, et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol. 2014;15(12):1332–1341.
   PubMed Web of Science ®Google Scholar
• NCCN guidelines: NCCN Guidelines Version 8; 2020. Non-Small Cell Lung Cancer; http://www.nccn.org.
   Google Scholar
• Iguchi T, Hiraki T, Matsui Y, et al. Survival outcomes of treatment with radiofrequency ablation, stereotactic body radiotherapy, or sublobar resection for patients with clinical stage I non-small-cell lung cancer: a single-center evaluation. J Vasc Interv Radiol. 2020;31(7):1044–1051.
   PubMed Web of Science ®Google Scholar
• Liang L, Li G, Xie S, et al. Choice of treatment for stage IA non-small cell lung cancer patients ineligible for surgery: ablation or stereotactic body radiotherapy. J Cancer. 2020;11(6):1634–1640.
   PubMed Web of Science ®Google Scholar
• Watson RA, Tol I, Gunawardana S, et al. Is microwave ablation an alternative to stereotactic ablative body radiotherapy in patients with inoperable early-stage primary lung cancer. Interact Cardiovasc Thorac Surg. 2019;29(4):539–543.
   PubMed Web of Science ®Google Scholar
• Lam A, Yoshida EJ, Bui K, et al. A national cancer database analysis of radiofrequency ablation versus stereotactic body radiotherapy in early-stage non-small cell lung cancer. J Vasc Interv Radiol. 2018;29(9):1211–1217.e1.
   PubMed Web of Science ®Google Scholar
• Ager BJ, Wells SM, Gruhl JD, et al. Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer. Lung Cancer. 2019;138:6–12.
   PubMed Web of Science ®Google Scholar
• Healey TT, March BT, Baird G, et al. Microwave ablation for lung neoplasms: a retrospective analysis of long-term results. J Vasc Interv Radiol. 2017;28(2):206–211.
   PubMed Web of Science ®Google Scholar
• Tan L, Chen S, Wei G, et al. Sublethal heat treatment of hepatocellular carcinoma promotes intrahepatic metastasis and stemness in a VEGFR1-dependent manner. Cancer Lett. 2019;460:29–40.
   PubMed Web of Science ®Google Scholar
• Cheng J, Li M, Lv Y. Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology. 2014;59(4):1650.
   PubMed Web of Science ®Google Scholar
• Ouyang Y, Liu K, Hao M, et al. Radiofrequency ablation-increased CXCL10 is associated with earlier recurrence of hepatocellular carcinoma by promoting stemness. Tumour Biol. 2016;37(3):3697–3704.
   PubMedGoogle Scholar
• Kong P, Pan H, Yu M, et al. Insufficient microwave ablation-induced promotion of distant metastasis is suppressed by β-catenin pathway inhibition in breast cancer. Oncotarget. 2017;8(70):115089–115101.
   PubMedGoogle Scholar
• Zaimoku R, Miyashita T, Tajima H, et al. Monitoring of heat shock response and phenotypic changes in hepatocellular carcinoma after heat treatment. Anticancer Res. 2019;39(10):5393–5401.
   PubMed Web of Science ®Google Scholar
• Zhang N, Li H, Qin C, et al. Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteins. J Cancer Res Clin Oncol. 2019;145(4):895–907.
   PubMed Web of Science ®Google Scholar
• Xu WL, Wang SH, Sun WB, et al. Insufficient radiofrequency ablation-induced autophagy contributes to the rapid progression of residual hepatocellular carcinoma through the HIF-1α/BNIP3 signaling pathway. BMB Rep. 2019;52(4):277–282.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Kornek M, Ikenaga N, et al. Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology. 2013;58(5):1667–1680.
   PubMed Web of Science ®Google Scholar
• Yang Y, Xiao M, Song Y, et al. H-score of 11β-hydroxylase and aldosterone synthase in the histopathological diagnosis of adrenocortical tumors. Endocrine. 2019;65(3):683–691.
   PubMed Web of Science ®Google Scholar
• Shu C, Zha H, Long H, et al. C3a-C3aR signaling promotes breast cancer lung metastasis via modulating carcinoma associated fibroblasts. J Exp Clin Cancer Res. 2020;39(1):11.
   PubMed Web of Science ®Google Scholar
• Wang H, Li M, Rinehart JJ, et al. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res. 2004;10(5):1633–1644.
   PubMed Web of Science ®Google Scholar
• Hiraki T, Gobara H, Mimura H, et al. Percutaneous radiofrequency ablation of clinical stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2011;142(1):24–30.
   PubMed Web of Science ®Google Scholar
• Donington JS. Radiofrequency ablation in high-risk stage I non-small cell lung cancer. Cancer. 2015;121(19):3393–3394.
   PubMed Web of Science ®Google Scholar
• Hiraki T, Gobara H, Iguchi T, et al. Radiofrequency ablation for early-stage nonsmall cell lung cancer. Biomed Res Int. 2014;2014:152087.
   PubMed Web of Science ®Google Scholar
• Lanuti M, Sharma A, Willers H, et al. Radiofrequency ablation for stage I non-small cell lung cancer: management of locoregional recurrence. Ann Thorac Surg. 2012;93(3):921–927. discussion 927-88.
   PubMed Web of Science ®Google Scholar
• Simon CJ, Dupuy DE, DiPetrillo TA, et al. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology. 2007;243(1):268–275.
   PubMed Web of Science ®Google Scholar
• Hiraki T, Gobara H, Iguchi T, et al. Radiofrequency ablation as treatment for pulmonary metastasis of colorectal cancer. World J Gastroenterol. 2014;20(4):988–996.
   PubMed Web of Science ®Google Scholar
• Yang Q, Qi H, Zhang R, et al. Risk factors for local progression after percutaneous radiofrequency ablation of lung tumors: evaluation based on a review of 147 tumors. J Vasc Interv Radiol. 2017;28(4):481–489.
   PubMed Web of Science ®Google Scholar
• Lee TH, Bu J, Kim BH, et al. Sub-lethal hyperthermia promotes epithelial-to mesenchymal-like transition of breast cancer cells: implication of the synergy between hyperthermia and chemotherapy. RSC Adv. 2019;9(1):52–57.
   Web of Science ®Google Scholar
• Tong Y, Yang H, Xu X, et al. Effect of a hypoxic microenvironment after radiofrequency ablation on residual hepatocellular cell migration and invasion. Cancer Sci. 2017;108(4):753–762.
   PubMed Web of Science ®Google Scholar
• Wang X, Deng Q, Feng K, et al. Insufficient radiofrequency ablation promotes hepatocellular carcinoma cell progression via autophagy and the CD133 feedback loop. Oncol Rep. 2018;40(1):241–251.
   PubMed Web of Science ®Google Scholar
• Zhang R, Ma M, Lin XH, et al. Extracellular matrix collagen I promotes the tumor progression of residual hepatocellular carcinoma after heat treatment. BMC Cancer. 2018;18(1):901.
   PubMed Web of Science ®Google Scholar
• Liu Z, Dai H, Jia G, et al. Insufficient radiofrequency ablation promotes human hepatoma SMMC7721 cell proliferation by stimulating vascular endothelial growth factor overexpression. Oncol Lett. 2015;9(4):1893–1896.
   PubMed Web of Science ®Google Scholar
• Duan XH, Li H, Han XW, et al. Upregulation of IL-6 is involved in moderate hyperthermia induced proliferation and invasion of hepatocellular carcinoma cells. Eur J Pharmacol. 2018;833:230–236.
   PubMed Web of Science ®Google Scholar
• Zhang N, Ma D, Wang L, et al. Insufficient radiofrequency ablation treated hepatocellular carcinoma cells promote metastasis by up-regulation ITGB3. J Cancer. 2017;8(18):3742–3754.
   PubMed Web of Science ®Google Scholar
• Jiang K, Zhao T, Shen M, et al. MiR-940 inhibits TGF-β-induced epithelial-mesenchymal transition and cell invasion by targeting Snail in non-small cell lung cancer. J Cancer. 2019;10(12):2735–2744.
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–890.
   PubMed Web of Science ®Google Scholar
• Kang Y, Massagué J. Epithelial–mesenchymal transitions: twist in development and metastasis. Cell. 2004;118(3):277–279.
   PubMed Web of Science ®Google Scholar
• Tanco S, Zhang X, Morano C, et al. Characterization of the substrate specificity of human carboxypeptidase A4 and implications for a role in extracellular peptide processing. J Biol Chem. 2010;285(24):18385–18396.
   PubMed Web of Science ®Google Scholar
• Fu Y, Su L, Cai M, et al. Downregulation of CPA4 inhibits non small-cell lung cancer growth by suppressing the AKT/c-MYC pathway. Mol Carcinog. 2019;58(11):2026–2039.
   PubMed Web of Science ®Google Scholar
• Bademler S, Ucuncu MZ, Tilgen Vatansever C, et al. Diagnostic and prognostic significance of carboxypeptidase A4 (CPA4) in breast cancer. Biomolecules. 2019;9(3):103.
   Web of Science ®Google Scholar
• Sun L, Guo C, Burnett J, et al. Association between expression of Carboxypeptidase 4 and stem cell markers and their clinical significance in liver cancer development. J Cancer. 2017;8(1):111–116.
   PubMed Web of Science ®Google Scholar
• Sun L, Guo C, Yuan H, et al. Overexpression of carboxypeptidase A4 (CPA4) is associated with poor prognosis in patients with gastric cancer. Am J Transl Res. 2016;8(11):5071–5075.
   PubMed Web of Science ®Google Scholar
• Sun L, Guo C, Burnett J, et al. Serum carboxypeptidaseA4 levels predict liver metastasis in colorectal carcinoma. Oncotarget. 2016;7(48):78688–78697.
   PubMedGoogle Scholar
• Sun L, Burnett J, Guo C, et al. CPA4 is a promising diagnostic serum biomarker for pancreatic cancer. Am J Cancer Res. 2016;6(1):91–96.
   PubMed Web of Science ®Google Scholar
• Ross PL, Cheng I, Liu X, et al. Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer. BMC Cancer. 2009;9(1):69.
   PubMed Web of Science ®Google Scholar
• Shao Q, Zhang Z, Cao R, et al. CPA4 promotes EMT in pancreatic cancer via stimulating PI3K-AKT-mTOR signaling. OTT. 2020; 13:8567–8580.
   Web of Science ®Google Scholar
• Sun L, Wang Y, Yuan H, et al. CPA4 is a novel diagnostic and prognostic marker for human non-small-cell lung cancer. J Cancer. 2016;7(10):1197–1204.
   PubMed Web of Science ®Google Scholar
• Alonso del Rivero M, Reytor ML, Trejo SA, et al. A noncanonical mechanism of carboxypeptidase inhibition revealed by the crystal structure of the Tri-Kunitz SmCI in complex with human CPA4. Structure. 2013;21(7):1118–1126.
   PubMed Web of Science ®Google Scholar
• Su T, Liao J, Dai Z, et al. Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after insufficient radiofrequency ablation. Oncogene. 2018;37(26):3514–3527.
   PubMed Web of Science ®Google Scholar